Why Athletes Use Amlodipine: Blood Pressure Control in Active People

Amlodipine is among the most prescribed medications in the United States, and athletes are no exception. Sports cardiologists often choose it for active patients with high blood pressure because it rarely interferes with exercise. Our editorial team explains how the drug works, when it is appropriate, and why it should never be used to mask the cardiovascular effects of performance-enhancing drugs without medical care.

What amlodipine is and how it works

Amlodipine belongs to the dihydropyridine class of calcium channel blockers. It blocks L-type calcium channels in the smooth muscle of artery walls. With less calcium entering these cells, the arteries relax and widen, which lowers blood pressure.

Unlike non-dihydropyridine calcium channel blockers such as verapamil and diltiazem, amlodipine has little direct effect on heart rate or the heart's electrical conduction at usual doses. Its action is concentrated on blood vessels.

The drug has a very long half-life, roughly 30 to 50 hours according to its labeling, which allows once-daily dosing and produces steady blood levels. Missing a single dose usually does not cause a sudden rebound in blood pressure.

In the US, amlodipine is a prescription medication approved for hypertension and certain forms of angina. It is often combined in single pills with other drugs such as ARBs, ACE inhibitors or statins. The choice of dose and combination is made by a physician.

Why it suits active people

Blood pressure drugs differ in how they affect exercise. Beta-blockers reduce maximum heart rate and can limit performance in endurance sports. Diuretics may contribute to dehydration and electrolyte imbalance, especially in hot conditions, and are prohibited by WADA as potential masking agents.

Calcium channel blockers like amlodipine and renin-angiotensin system blockers (ACE inhibitors and ARBs) generally do not impair exercise capacity. The 2020 ESC guidelines on sports cardiology (Pelliccia et al.) list them as preferred options for athletes with hypertension.

Amlodipine is also a common choice for Black patients in the US, in whom calcium channel blockers and thiazide diuretics tend to lower blood pressure more effectively than renin-angiotensin system blockers used alone, as reflected in the 2017 ACC/AHA guideline (Whelton et al.).

Because amlodipine does not affect heart rate much, it does not interfere with heart rate–based training zones, which is an advantage for athletes who train with heart rate monitors.

Outcome evidence from major trials

Amlodipine has strong outcome data. In ALLHAT, one of the largest hypertension trials ever conducted, amlodipine was compared with the diuretic chlorthalidone and the ACE inhibitor lisinopril in more than 33,000 patients. Rates of the primary outcome, fatal coronary heart disease or nonfatal heart attack, were similar across groups, although heart failure was more common with amlodipine than with the diuretic.

The ASCOT-BPLA trial (Dahlöf et al., 2005) compared an amlodipine-based regimen with an atenolol-based regimen. The amlodipine group had fewer strokes, fewer cardiovascular events and lower total mortality, contributing to the decline of beta-blockers as first-line hypertension therapy.

The ACCOMPLISH trial (Jamerson et al., 2008) found that combining the ACE inhibitor benazepril with amlodipine reduced cardiovascular events more than combining benazepril with hydrochlorothiazide in high-risk patients. This supported the widespread use of amlodipine in combination therapy.

These trials studied mostly older patients with established hypertension and risk factors, not young athletes. The general principle, however, is clear: controlling blood pressure with well-studied drugs reduces stroke and heart disease.

Blood pressure and performance-enhancing drugs

Among strength athletes, high blood pressure is sometimes linked to anabolic-androgenic steroids, stimulants or growth hormone. Baggish and colleagues (2017) described how long-term steroid use is associated with elevated blood pressure, reduced heart pumping function and accelerated coronary artery disease.

Some users try to manage this by taking blood pressure medications on their own. This is risky for several reasons. Lowering the numbers does not reverse other harms such as heart muscle thickening, lipid changes or blood clotting tendency. Self-medication may also hide a worsening problem.

• Blood pressure medication does not make steroid or stimulant use safe.
• Unsupervised use can cause low blood pressure, fainting or kidney problems.
• Underlying heart damage requires cardiology evaluation, not just a pill.
• The most effective intervention is stopping the substance causing the problem.

Athletes who have used performance-enhancing drugs should be honest with their physician. Doctors are focused on safety, and full information leads to better decisions about testing, imaging and treatment.

Side effects, interactions and anti-doping rules

The most common side effect of amlodipine is swelling of the ankles and feet, which is dose-related and results from widening of small arteries rather than fluid overload. Headache, flushing, dizziness and palpitations can also occur, especially early in treatment.

Gum overgrowth is a less common effect. Athletes who notice swollen or bleeding gums should mention it to their dentist and doctor.

Amlodipine is metabolized by the liver enzyme CYP3A4, so strong inhibitors of that enzyme can increase its levels. Its US labeling recommends limiting simvastatin to 20 mg per day when taken with amlodipine because of increased statin exposure and muscle risk. Combining several blood pressure–lowering agents, alcohol or heavy sweating in hot conditions can amplify dizziness.

Amlodipine is not on the WADA Prohibited List. Athletes in tested sport should still confirm the status of any medication with USADA or their governing body, and declare it as required. As with any prescription drug, it should only be used with a medical indication.

The Editorial Team's Conclusions

Amlodipine is an effective, well-studied blood pressure medication that suits many active people because it does not reduce exercise capacity or heart rate response.

Large trials show it reduces cardiovascular events as part of hypertension treatment, particularly in combination with other drugs.

It is not a tool for offsetting the effects of performance-enhancing drugs. Athletes with high blood pressure deserve a full medical evaluation and treatment of the underlying cause.

You may also want to read our articles on losartan for athletes, on cardiovascular screening in strength sports, and on how stimulants affect blood pressure.

References

1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–2997.
2. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required (ASCOT-BPLA). Lancet. 2005;366(9489):895–906.
3. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417–2428.
4. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension. 2018;71(6):e13–e115.
5. Pelliccia A, Sharma S, Gati S, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. 2021;42(1):17–96.
6. Baggish AL, Weiner RB, Kanayama G, et al. Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation. 2017;135(21):1991–2002.
7. https://farmaciatletica.com/